The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. Our central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and/or chronicity of neuropathic pain.
18 years of age or older.
Established cancer-associated neuropathic pain.
A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4.
A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment.
Actively undergoing cancer treatment.
Symptoms and/or diagnosis of diabetic peripheral neuropathy.
Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis.
High probability of completing the study and all study-related measures/activities required by the protocol.